Expert Insights Newsletter

Photo

Paraneoplastic Autoantibody Syndromes—Diagnosing Neurological Disorders

Neuronal-specific autoantibodies have a variety of potential targets, and give rise to a range of dysfunctions and neurological syndromes. Diagnosing the associated syndromes can be challenging. Dr. Stanley Naides, Medical Director, Immunology R&D, Quest Diagnostics, discusses the mechanism and presentation... Read more 

Photo

Polycystic Ovary Syndrome (PCOS)—Making Sense of a Misunderstood Condition

Polycystic Ovary Syndrome (PCOS)—Making Sense of a Misunderstood Condition Polycystic ovary syndrome (PCOS) is a commonly misunderstood condition with a misleading name. Dr. Andrea Dunaif, Charles F. Kettering Professor of Endocrinology and Metabolism, Northwestern University Feinberg School of Medicine, explains... Read more 

Photo

Management of Patients with Diabetes and Resistant Hypertension

Diabetic patients with hypertension have an increased risk of cardiovascular disease (CVD), necropathy, and chronic kidney disease compared with non-diabetics.1 Resistant hypertension is particularly concerning among diabetics. Dr. Vivian Fonseca, Professor of Medicine and Pharmacology, Tulane University Health Sciences Center,... Read more 

Photo

Mass Spectrometry—Applying the Gold Standard in Endocrinology

The availability of mass spectrometry is enabling higher levels of precision and reliability in laboratory diagnostics than has traditionally been possible. Dr. Michael J. McPhaul, Medical Director, Endocrinology and Metabolism, Quest Diagnostics discusses the growing application of mass spectrometry in... Read more 

Photo

Big Data Analytics in Healthcare – How Laboratories Can Play a Leading Role

The capture and analysis of big data offers considerable potential to improve the quality of healthcare and gain insights into public health. Dr. Harvey Kaufman, Senior Medical Director, Quest Diagnostics, discusses this potential, and the important role laboratories can play... Read more 

Photo

Hepatitis C Virus – Identifying and Managing Resistance Associated Variants

The introduction of direct-acting antiviral agents (DAAs) has transformed hepatitis C virus (HCV) treatment over the last 18 months. While the majority treated are effectively cured after a regimen of typically 12 weeks, there is a significant minority who are... Read more